Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Recruiting

Phase 3

Sponsor:

Jazz Pharmaceuticals

Code:

NCT04485104

Conditions

Seizure in Participants With Tuberous Sclerosis Complex

Seizure in Participants With Dravet Syndrome

Seizure in Participants With Lennox-Gastaut Syndrome

Eligibility Criteria

Sex: All

Age: 1 - 23

Healthy Volunteers: Not accepted

Interventions

GWP42003-P

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information